CHICAGO — Patients with dry age-related macular degeneration experienced sustained improvements in best correct visual acuity at month 13 of the LIGHTSITE III pivotal clinical trial, according to a study presented at Eyecelerator@AAO.
Clark E. Tedford, PhD, president and CEO of LumiThera, said the Valeda light delivery system uses a multiple wavelength approach with LEDs to provide a short treatment to stimulate mitochondrial markers.
“We do nine sessions over the course of about 3 to 4 weeks,” he said. “It takes a little over 4 minutes per eye, and we can do both eyes